SEC Form 4 · accession 0000899243-18-000796
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adelene Q Perkins
Officer — Chief Executive Officer · Director
Period of report
Jan 8, 2018
Accepted (ET)
Jan 9, 2018 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.985 | Jan 8, 2018 | A | 500,000 | A | — | Jan 8, 2028 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1The option vests as to 50% of the shares on May 25, 2018, and as to the remaining 50% of the shares on May 25, 2019.